Condition:   Bioavailability
Interventions:   Drug: Dexlansoprazole Delayed Release Orally Disintegrating Tablets;   Drug: Dexlansoprazole Delayed Release Capsules
Sponsor:   Takeda
Not yet recruiting - verified February 2014

Condition:   Early Gastric Cancer or Gastric Adenoma
Interventions:   Drug: intravenous dexamethasone;   Drug: intravenous normal saline
Sponsor:   Yonsei University
Recruiting - verified January 2014

Condition:   Clostridium Difficile Infection
Interventions:   Drug: Lansoprazole;   Other: Standard of Care
Sponsor:   Columbia University
Not yet recruiting - verified December 2013

Condition:   Gastroesophageal Reflux Disease With Dyspepsia Symptoms
Intervention:   Drug: Lansoprazole
Sponsor:   Takeda
Completed - verified November 2013

Conditions:   Premature Infants;   Gastroesophageal Reflux
Interventions:   Drug: Lansoprazole;   Drug: Placebo
Sponsors:   Seoul National University Hospital;   Seoul National University Hospital
Active, not recruiting - verified September 2013

Condition:   Helicobacter Infections
Intervention:   Drug: PPI triple therapy
Sponsors:   Seoul National University Bundang Hospital;   Seoul National University Bundang Hospital
Completed - verified August 2013

Condition:   Helicobacter Pylori Infection
Intervention:   Drug: triple, quadruple, non-bismuth quadruple therapy
Sponsors:   National Taiwan University Hospital;   National Taiwan University Hospital
Not yet recruiting - verified June 2013

Conditions:   Dyspepsia;   Helicobacter-associated Gastritis;   Stomach Disorders
Interventions:   Drug: Double dose of PPI;   Drug: sequence of drug use
Sponsors:   Mahidol University;   Mahidol University;   Takeda Pharmaceuticals International, Inc.
Recruiting - verified June 2013

Condition:   Healthy
Intervention:   Drug: lansoprazole, 30 mg per day for 6 days
Sponsors:   Xijing Hospital;   Xijing Hospital
Not yet recruiting - verified March 2013

Conditions:   Preterm Infants;   Gastrointestinal Reflux
Intervention:   Drug: Lansoprazole
Sponsors:   Seoul National University Hospital;   Seoul National University Hospital
Recruiting - verified January 2013

Condition:   Type 1 Diabetes
Interventions:   Drug: Oral Cyclosporine and Placebo;   Drug: Lansoprazole and Placebo;   Drug: Oral Cyclosporine and Oral Lansoprazole;   Drug: Placebos
Sponsors:   Perle Bioscience, LLC.;   Perle Bioscience, LLC.
Not yet recruiting - verified January 2013

Condition:   Type 1 Diabetes
Interventions:   Drug: Oral Cyclosporine and Placebo;   Drug: Oral Lansoprazole and Placebo;   Drug: Oral Cyclosporine and Oral Lansoprazole;   Drug: Oral Placebos
Sponsors:   Perle Bioscience, LLC.;   Perle Bioscience, LLC.
Not yet recruiting - verified January 2013

Condition:   Healthy Volunteers
Interventions:   Drug: LY2940680 Capsule(s) (Reference);   Drug: LY2940680 Tablet (Test);   Drug: Lanzoprazole;   Drug: Placebo Capsule(s)
Sponsors:   Eli Lilly and Company;   Eli Lilly and Company
Active, not recruiting - verified December 2012

Conditions:   Gastric Cancer;   Bacterial Infection Due to Helicobacter Pylori (H. Pylori)
Interventions:   Drug: Placebo;   Drug: LAC triple therapy
Sponsors:   National Cancer Center, Korea;   National Cancer Center, Korea
Active, not recruiting - verified August 2012

Conditions:   Functional Dyspepsia;   Scarred Peptic Ulcer
Interventions:   Drug: Proton Pump Inhibitor;   Drug: Bismuth;   Drug: Metronidazole;   Drug: Tetracycline;   Drug: Furazolidone;   Drug: Amoxicillin
Sponsors:   Shanghai Jiao Tong University School of Medicine;   Shanghai Jiao Tong University School of Medicine
Recruiting - verified July 2012

Condition:   Gastroesophageal Reflux Disease
Intervention:   Drug: Dexlansoprazole
Sponsors:   Takeda Global Research & Development Center, Inc.;   Takeda Global Research & Development Center, Inc.
Not yet recruiting - verified July 2012

Conditions:   Gastroesophageal Reflux Disease;   Erosive Esophagitis
Interventions:   Drug: Dexlansoprazole;   Drug: Dexlansoprazole;   Drug: Placebo
Sponsors:   Takeda Global Research & Development Center, Inc.;   Takeda Global Research & Development Center, Inc.
Not yet recruiting - verified July 2012

Condition:   Eradication Rate for Helicobacter
Interventions:   Drug: levofloxacin-based sequential therapy;   Drug: levofloxacin-based triple therapy for 10 days
Sponsors:   National Taiwan University Hospital;   E-DA Hospital
Not yet recruiting - verified January 2012

Condition:   Coronary Stenting
Intervention:   Drug: Lansoprazole
Sponsor:   Università degli Studi di Ferrara
Recruiting - verified January 2012

Conditions:   Erosive Esophagitis;   GERD
Interventions:   Drug: Ilaprazole;   Drug: Lansoprazole
Sponsor:   Il-Yang Pharm. Co., Ltd.
Completed - verified January 2012